New
HealthMore in Health →
Otsuka’s $700 Million Upfront Deal for Transcend Signals Continued Bet on Next-Generation Neuropsychiatric Drugs
Otsuka is acquiring private biotech Transcend Therapeutics in a deal worth roughly $1.2 billion, extending big pharma’s interest in neuropsychiatric medicines modeled on the therapeutic promise associated with psychedel
Key Takeaways
- Otsuka will pay $700 million upfront to acquire Transcend Therapeutics.
- The transaction is worth roughly $1.2 billion in total.
DE
DT Editorial AI··via endpoints.news